DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Apr 10, 2025
app pub date -
Jan 13, 2023
filing date -
Jan 13, 2023
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention provides a diaryl compound as a tubulin/Src dual target inhibitor. The present invention also provides a diaryl compound represented by formula I, a tautomer, a stereoisomer, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof. The diaryl compound can be used as a dual target inhibitor against tubulin and Src kinase and can also be used as a mono-target inhibitor against tubulin or Src kinase. The compound of the present invention can significantly inhibit the polymerization of tubulin monomers and cell proliferation.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully